In February, the Chilean Servicio Agricola y Ganadero (SAG) provided a provisional marketing authorization for Pharmaq’s vaccine ALPHA JECT LiVac®. This is seen as an important defence in protecting the country’s salmon industry from Salmon Rickettsial Septicaemia (SRS) Syndrome, one of the most serious fish diseases in the nation.
Salmon Rickettsial Septicaemia (SRS) or Piscirickettsiosis is caused by the bacterium Piscirickettsia salmonis, generating a severe disease that has caused economic losses in the aquaculture industry since its appearance in 1989. The disease affects all three species farmed in Chile: Atlantic salmon, rainbow trout and coho salmon.
“We are confident that this ground-breaking vaccine will be an important tool to help fight (and control) SRS,” says Pharmaq president Morten Kr. Nordstad. “This is a highly requested product by the industry and will help achieve more predictable and reliable fish production.”